

Breastmilk IgG engages the murine neonatal immune system to instruct responses to gut antigens

Meera K. Shenoy^{1,6}, Diane M. Rico^{1†}, Alina K. Lorant^{1†}, Hamadoun Touré¹, Shannon Gordon^{1‡}, Luke J. Milburn¹, Jeanette S. Schwensen^{2,4,5}, Madelyn E. Cabán^{1,3}, Meghan A. Koch^{1,3*}

¹Basic Sciences Division, Fred Hutchinson Cancer Center; Seattle, WA, 98109, USA.

²Translational Science and Therapeutics Division, Fred Hutchinson Cancer Center; Seattle, WA, 98109, USA.

³Department of Immunology, University of Washington; Seattle, WA, 98195, USA.

⁴Molecular and Cellular Biology Graduate Program, University of Washington; Seattle, WA, 98195, USA.

⁵Medical Scientist Training Program, University of Washington; Seattle, WA, 98195, USA.

⁶Singapore Immunology Network (SIgN), Agency for Science, Technology and Research (A*STAR); 8a Biomedical Grove, Immunos, Singapore, 138648, Republic of Singapore.

*Corresponding author. mkoch@fredhutch.org

†These authors contributed equally to this work.

‡Present address: University of Chicago, Chicago, IL, 60637, USA

One sentence abstract: Ingestion of breastmilk IgG during a discrete postnatal window tunes neonatal immunity to the gut microbiota.

Abstract

Maternal antibodies fundamentally regulate gut immunity in the developing infant, yet the mechanisms underlying this process remain elusive. We found that maternal IgG, ingested in the first week of life, restrained microbiota-dependent adaptive immune responses weeks later, following weaning. This activity was linked to maternal antibodies that could bind bacteria in the neonatal gut and the ability of microbe-IgG complexes to engage Fc and complement-dependent effector functions in offspring. Ingestion of microbiota-specific maternal IgG also limited aberrant neonatal responses to dietary antigens encountered at weaning. These discoveries suggest that maternal IgG engages the immune system of offspring in early postnatal life to modulate mucosal responses and reinforce intestinal homeostasis in the face of dynamic shifts in food and bacterial antigens during development.

39 Introduction

40 A fundamental function of the immune system is to promote mutualism between the host
41 and resident microbiota. In the gut, this process enables the host to harness numerous benefits
42 from microbes, including expanded nutrient assimilation, immune education, and resistance to
43 pathogen colonization, while mitigating risks such as toxin exposure, chronic inflammation, and
44 pathobiont invasion (1-3). In early life, establishing immune tolerance toward the microbiota while
45 avoiding inappropriate inflammation is complicated by the dynamic nature of the neonatal
46 period—marked by rapid changes in microbiota and food antigen composition. Studies linking
47 perturbations in infant microbiota exposure or assembly with increased risk of metabolic and/or
48 inflammatory diseases underscore the importance of this process (4-8). Ingested immediately
49 post-birth, breastmilk is poised to regulate nascent host-microbiota interactions. Along with
50 nutrients, breastmilk provides offspring with live bacteria, maternal immune cells, and
51 immunomodulatory molecules, including cytokines and immunoglobulins (9, 10).

52 Multiple antibody isotypes, including IgA and IgG, are readily detectable in breastmilk,
53 though the relative abundance of these isotypes differs based on species. For example, murine
54 milk contains proportionately higher levels of IgG compared to that of humans (11). Pioneering
55 work by Kramer and Cebra revealed that young mice reared by dams lacking B and T cells exhibit
56 increased T cell-dependent germinal center (GC) reactions in gut-associated lymphoid tissues,
57 including Peyer's patches (PP) and mesenteric lymph nodes (mLN), indicating that maternal
58 antibodies regulate homeostatic gut immunity (12). In subsequent studies, we solidified the
59 importance of breastmilk antibodies (rather than maternal T cells) in this process by using mothers
60 with a targeted disruption of the mu heavy chain gene (μ MT^{-/-}). These mice lack mature B cells
61 and are deficient in antibodies. Wild-type C57Bl/6 (B6) offspring reared by μ MT^{-/-} dams exhibit
62 similar immune dysregulation, characterized by heightened GC T follicular helper (Tfh) and GC B
63 cell frequencies and numbers in the mLN and PP (13). This response is transient, with elevated
64 Tfh responses peaking around postnatal days 25-26 (p25-26) and normalizing to wild-type levels
65 at later time points. Additional studies in humans and mice have shown that breastmilk antibodies
66 readily bind infant gut microbes and can help shape the assembly of the microbiome, promote
67 barrier function, restrain inflammatory responses to commensal microbes, and guide the
68 abundance of mucosal T cell subsets (9, 10, 12-16).

69 The prevailing model of immune instruction mediated by maternal antibodies is largely
70 based on studies of IgA-directed regulation of enteric pathogens and certain gut commensal
71 strains in adult mice (17-23). However, this model does not account for substantial differences in
72 gut physiology, such as increased barrier permeability in early life, altered microbiota composition,
73 and the presence of other antibody isotypes - such as breastmilk-derived IgG - in the infant gut
74 (13, 24-27). As such, the mechanisms underlying antibody function at the maternal-offspring
75 interface remain unclear. Here, we developed a murine model enabling precise control over the
76 timing and composition of breastmilk antibodies, the microbiota, and the infant immune system to
77 delineate the mechanisms by which breastmilk antibodies tune offspring immunity to newly
78 encountered mucosal antigens.

79

80 Results

81 ***Early-life acquisition of breastmilk antibodies restrains mucosal adaptive immune*** 82 ***responses following weaning.***

83 Mucosal immunity is heavily influenced by the microbiota, which can vary substantially
84 between different housing conditions and physical locations (28, 29). Thus, to confirm that Tfh-
85 driven immune dysregulation is a common feature of breastmilk antibody deficiency, we assessed
86 responses in mice maintained at the Fred Hutchinson Cancer Center in Seattle, WA. Mirroring
87 our prior findings with neonates housed at UC Berkeley, Berkeley, CA (13), we found that the
88 acquisition of breastmilk antibodies during the entire pre-weaning period, from birth to 21 days

89 (p0-p21), prevented mucosal immune dysregulation. Four days after weaning (p25), the offspring
90 of μ MT^{-/-} dams and B6 sires had elevated Tfh numbers and frequencies in the mLN (marked as
91 CD4⁺Foxp3⁻CD44⁺PD-1⁺CXCR5^{hi}Bcl6⁺) (**Fig S1A**), compared to control pups of B-cell sufficient,
92 μ MT^{+/-} dams (**Figs 1A, B**). These differences were also observed in the PP and corresponded
93 with elevated GC B cell responses, as distinguished by the number and frequency of
94 CD19⁺IgD^{lo}B220⁺PNA⁺GL7⁺ cells (**Figs S1B – D**). We performed similar experiments with a
95 distinct model of B cell deficiency by using Jh^{-/-} dams, which are completely devoid of mature B
96 cells and antibodies due to a targeted deletion of JH gene segments. Further, to rule out strain-
97 specific effects in maternal antibody function, we used Jh^{-/-} on the Balb/c background, which is
98 genetically distinct from the C56Bl/6 background of μ MT^{-/-} mice. We observed similar immune
99 dysregulation in p25 offspring of B cell-deficient Jh^{-/-} dams and wild-type (WT) sires (**Figs S1E,**
100 **F**). Having established that heightened mLN Tfh cell abundance was consistently observed in
101 neonates lacking maternal antibodies, we focused on this response as a ‘readout’ to decipher the
102 mechanisms involved in breastmilk antibody function.

103 Establishing intestinal homeostasis relies on a series of coordinated events occurring
104 during distinct developmental phases, such as microbiota seeding and diversification, innate
105 immune hyporesponsiveness, and controlled transport of luminal antigens (30). To determine
106 whether breastmilk antibody transfer during a specific postnatal window was required to regulate
107 mucosal immunity, we cross-fostered the offspring of μ MT^{+/-} and μ MT^{-/-} dams and B6 sires at
108 different ages (**Fig 1A**). The microbiome can vary markedly between non-cohoused, non-
109 littermate animals, driving intestinal alterations that are independent of genetically encoded
110 immune factors, such as maternal antibodies (31). Thus, to maximally homogenize the microbiota
111 between birth mothers, offspring, and foster mothers, littermate, cohoused μ MT^{+/-} and μ MT^{-/-}
112 dams were only separated briefly, first for breeding with sires and then again before parturition
113 and through offspring weaning. Progeny of μ MT^{+/-} dams fostered to antibody-deficient μ MT^{-/-} dams
114 after the first week of life (p7 or later) harbored reduced frequencies and numbers of Tfh and GC
115 B cells compared to pups fostered at birth (p0) (**Fig 1C, Figs S1G, H**). Additionally, μ MT^{-/-} dam-
116 born pups fostered to antibody-sufficient μ MT^{+/-} dams at p0 did not exhibit immune dysregulation,
117 whereas elevated mucosal Tfh and GC B cell responses were apparent in littermate counterparts
118 fostered after p7 (**Fig 1D, Figs S1G, I**). These findings indicated that antibody ingestion during
119 the first week of life regulates homeostatic immune development in the gut.

120
121 Maternal antibodies have been described to promote intestinal barrier function in offspring
122 at weaning (15). However, we found no difference in the accumulation of type 3 innate lymphoid
123 cells (ILC3) or the amount of IL-22 in the lamina propria, factors important for maintaining gut
124 barrier function (**Figs S2A – C**). Direct tests of barrier function via gavage of the non-digestible
125 substrate FITC-dextran or a lab strain of E. coli (K-12) also revealed no difference in the
126 translocation of these substances between young maternal antibody-sufficient and -deficient mice
127 (**Figs S2D, E**).

128
129 A network of antigen-presenting cells (APCs) directs the differentiation of effector T cells
130 in gut-draining lymphoid tissues. Thus, we considered that differences in mLN APC composition
131 could precede the Tfh immune dysregulation in mice lacking maternal antibodies (32, 33).
132 Analysis at p21, prior to the elevated Tfh and GC B cell responses observed in these offspring,
133 revealed only modest alterations in mLN APCs, including type-1 and -2 conventional dendritic
134 cells (cDC1 and cDC2), F4/80⁺ macrophages, and CX₃CR1⁺ mononuclear phagocytes (MNPs;
135 (34) **Fig S2F, G**). These findings demonstrated that the absence of maternal antibodies did not
136 impair intestinal barrier function nor broadly alter the distribution of mLN APC subsets.

137
138 ***Kinetics of murine antibody consumption and gut permeability during development***

139 To understand how breastmilk antibodies regulated intestinal homeostasis, we assessed
140 breastmilk consumption and composition over time (**Fig S3A**). Breastmilk intake increased as a
141 function of age (**Fig S3B**), and the total immunoglobulin concentration in milk (the sum of IgG,
142 IgA, and IgM; IgE was not detected) was largely stable during the first two weeks of lactation. Milk
143 from dams 0-7 days postpartum contained more IgG than those sampled later, consisting of
144 approximately 30% IgG1, 30% IgG2b, 35% IgG2c, and 5% IgG3 (**Figs 1E, F**). Extrapolating data
145 on milk intake and antibody concentrations, we estimate pups in our mouse colony consumed
146 244 $\mu\text{g/day}$ of IgG and 17 $\mu\text{g/day}$ IgA on average in the first week of life (**Fig S3C**).

147
148 The gastrointestinal tract undergoes developmentally regulated physiological changes
149 characterized by alterations in antimicrobial peptides, mucus, nutrient transporters, and barrier
150 permeability (35, 36). In healthy human infants, gut permeability to small sugars is increased
151 during the first week of life (37), and one study reported translocation of IgA dimers (~300 kDa)
152 in term babies orally administered IgA within 24 hours post-birth (38). These observations
153 prompted us to assess if the window of breastmilk antibody acquisition required to dampen
154 offspring immunity correlated with gut barrier permeability to ingested IgG. To directly evaluate
155 IgG translocation in the absence of cognate antigens or endogenous maternal- or offspring-
156 derived IgG, we orally administered an isotype-control IgG2b (normalized mg/kg) to $\mu\text{MT}^{-/-}$
157 progeny of $\mu\text{MT}^{-/-}$ dams. Two hours after treatment, we detected higher levels of (total) serum
158 IgG2b in p0-7 pups compared to older offspring (**Fig 1G**). We observed a similar heightened
159 translocation of ovalbumin-specific IgG1 or 150kDa Fluorescein-conjugated dextran (similar
160 molecular weight to IgG) in young (p0-7) wild-type B6 pups (**Figs 1H, I**), ruling out the possibility
161 that the increase in barrier permeability resulted from developmental defects in $\mu\text{MT}^{-/-}$ animals.
162 Thus, the mouse gut was more permeable to luminal substrates during the first week of life, the
163 same window during which maternal antibodies must be ingested to establish intestinal
164 homeostasis.

165 ***Oral IgG can prevent mucosal immune dysregulation in offspring***

166 To define the maternal antibody isotypes required to prevent immune dysregulation, we
167 fractionated IgG from IgA, IgM, and other milk proteins using Protein A columns (**Fig 2A**). We
168 confirmed the efficient isolation of IgG subclasses and overall purity of fractionated milk IgG
169 (>98%), whereas the flow-through (m Δ IgG) was enriched for IgA (**Fig 2B**).

170 We then performed 'add-back' experiments wherein we fed littermate, maternal antibody-
171 deficient offspring fractionated milk antibodies, thus allowing a direct comparison of co-housed
172 littermates born to and reared by the same mother, and avoiding potential confounding variables
173 introduced by maternal microbiota, antibody concentrations, or housing conditions (31). We fed
174 maternal antibody-deficient offspring 0.5 μg of milk IgG (mIgG), 1 μg milk IgA (m Δ IgG, also
175 harboring other proteins), or 1 μg BSA (irrelevant protein antigen) daily from p0 to p7 (**Fig 2A**). At
176 p25, neonates fed mIgG exhibited reduced mLN Tfh cell responses compared to pups
177 administered BSA or m Δ IgG (**Figs 2C, S4A**). Low pregnancy rates from timed breedings and
178 unanticipated pup attrition due to natural behaviors (e.g., cannibalism) made it difficult to generate
179 large numbers of offspring for each experimental group (39, 40). Thus, for this experiment and
180 others where obtaining a high n was difficult, we show two or more combined replicates. We
181 obtained similar results to mIgG using IgG purified from sera of wild-type C57Bl/6 mice in our
182 mouse colony (slgG), wherein administration of slgG, but not serum depleted of IgG (s Δ IgG; of
183 which IgM was the dominant isotype), BSA, or PBS, resulted in fewer mLN Tfh cells in p25
184 progeny of $\mu\text{MT}^{-/-}$ dams and B6 sires (**Figs 2D, E, S4B**).

185 Although the magnitude of the immune dysregulation varied between litters, mLN Tfh cell
186 responses were consistently lower in pups fed slgG compared to littermate controls given s Δ IgG
187 (**Figs 2F, S4C**). Administration of slgG to offspring reared by $\mu\text{MT}^{-/-}$ dams did not impact the
188

189 accumulation of other differentiated mLN CD4 T cell populations that serve important functions in
190 mucosal immunity, including T-bet⁺ (T helper type 1, Th1) and ROR γ t⁺ (Th17) effector subsets
191 nor Foxp3⁺ regulatory T cell subsets (41, 42) (**Fig S4D, E**).

192 Oral IgG was also able to dampen mLN Tfh responses using a distinct model of maternal
193 antibody deficiency achieved by breeding B cell-deficient C57/Bl6 Jh^{-/-} dams with B6 sires (**Fig**
194 **S4F**). The ability of IgG to prevent mucosal immune dysregulation indicated that the absence of
195 antibodies, rather than an unrelated perturbation in the milk or the behavior of B cell-deficient
196 mothers, triggered aberrant intestinal immunity. Dose-response experiments revealed that as little
197 as 1 μ g/day sIgG during p0-7 was sufficient to fully restrain mesenteric Tfh cell responses in p25
198 offspring of μ MT^{-/-} dams and B6 sires (**Figs 2G, S4G**). As mouse serum is more plentiful than
199 milk, and milk lipoproteins impede the efficient purification of IgG, we used sIgG for the remaining
200 studies.

201 ***The interplay between maternal antibodies, the postnatal microbiome, and homeostatic*** 202 ***intestinal immunity***

203 The selective elevation of Tfh cell responses at mucosal (e.g., mLN and PP) but not
204 systemic sites (e.g., spleen (13)), prompted us to examine the role of the gut microbiota in driving
205 immune dysregulation in offspring lacking maternal antibodies. We first analyzed ‘sterile’ mice
206 maintained under germ-free (GF) conditions and thus devoid of gut bacteria. Offspring of GF
207 B6.Jh^{-/-} dams and wild-type sires harbored equivalent, low frequencies and numbers of mucosal
208 Tfh cells, regardless of maternal antibody acquisition (**Figs 3A, S5A**). As a complementary
209 approach, we treated mice with a cocktail of broad-spectrum antibiotics composed of ampicillin,
210 vancomycin, neomycin, and metronidazole (AVNM) immediately prior to the height of the Tfh
211 response (p17-24 (43); **S5B**). While AVNM reduced Tfh cell frequencies and numbers in maternal
212 antibody-deficient offspring, this response was still elevated compared to maternal antibody-
213 sufficient progeny that received antibiotics (**Figs S5C – D**). This increase could result from
214 incomplete microbial elimination or changes in microbial composition following AVNM treatment
215 (43, 44). Alternatively, it is possible that other mucosal antigens, such as dietary components,
216 contributed to immune dysregulation in mice lacking maternal antibodies. Weaning pups earlier
217 (p18) or later (p25) than the standard of p21 resulted in similar immune dysregulation, indicating
218 that this response was not controlled by the cessation of breastfeeding (**Figs 3B, S5E**). Together,
219 these observations suggested that the microbiota triggered a homeostatic Tfh cell response
220 following weaning and that maternal antibodies controlled the magnitude of this response.

221 Antibodies are key regulators of gut microbiota diversity and composition (16, 45-47),
222 leading us to explore whether alterations in microbiome assembly correlated with immune
223 dysregulation in maternal antibody-deficient offspring. 16S rRNA gene sequencing of ileal and
224 colonic contents (**Fig S6A**) did not reveal substantial differences in the diversity of microbes in
225 each sample (alpha diversity) nor between-group distances (beta diversity) between age-matched
226 offspring of μ MT^{+/-} or μ MT^{-/-} littermate dams and B6 sires (**Figs S6B – E**). However, the
227 abundance of a small subset of taxa differed between p7 offspring of μ MT^{+/-} and μ MT^{-/-} dams, and
228 this variation increased with age (**Figs 3C, D and S6F – H**). Thus, the absence of all breastmilk
229 antibodies correlated with minor alterations in the assembly of the postnatal microbiome. Analysis
230 of p20 progeny of μ MT^{-/-} dams and B6 sires fed sIgG or BSA during the first week of life similarly
231 failed to reveal differences in alpha or beta diversity as a function of feeding (**Figs 3E, and S7A**
232 **– C**). Instead, litter was a driving factor (**Figs 3F, S7D**). Indeed, the provision of IgG resulted in
233 the differential abundance of only a single ileal taxon and two colonic taxa (**Figs 3G, S7E**), which
234 were distinct from those identified in p21 offspring of μ MT^{+/-} and μ MT^{-/-} dams. Taken together with
235 results from littermate mice in **Fig 2F** and **Fig S4C**, these data demonstrated that the ability of
236 early-life IgG to regulate neonatal immunity was robust to natural microbiome variation between

237 litters. Additionally, the similarity in microbiota community structure between IgG- and BSA-fed
238 littermates indicates that breastmilk IgG could regulate neonatal immunity without altering the
239 composition of the developing microbiome.

240 ***Early life IgG-microbe immune complexes prevent intestinal immune dysregulation***

241 The acquisition of maternal antibodies via breastfeeding, rather than placental transfer,
242 was required to prevent Tfh-driven immune dysregulation (**Fig 1B – D** and (13)). Serum analysis
243 of p7 offspring of μ MT^{+/-} or μ MT^{-/-} dams and B6 sires cross-fostered at birth revealed that mice
244 receive a substantial amount of maternal IgG via breastfeeding as opposed to during gestation
245 (**Figs 4A, S8A**). We found that maternal antibody-deficient pups fed sIgG harbored even lower
246 serum IgG titers compared to offspring that only received maternal antibodies *in utero* (**Figs 4A,**
247 **S8A**). As feeding pups sIgG was sufficient to reduce mucosal Tfh responses, these findings rule
248 out the possibility that the immune dysregulation observed in pups nursed by antibody-deficient
249 dams resulted from insufficient amounts of circulating IgG and indicated that the route of
250 acquisition (i.e., oral) underlies the immunoregulatory function of maternal IgG.

251
252 These observations prompted us to hypothesize that maternal IgG must bind to neonatal
253 gut microbes to regulate mucosal immunity. We assessed the antibody binding profiles of milk
254 and serum using microbiota-flow cytometry (mFLOW, (13) **FigS8B**). To avoid pre-coating of infant
255 bacteria by maternal antibodies, we used gut contents from μ MT^{-/-} pups (p6-8). IgG antibodies
256 from either milk or serum bound a substantial fraction of the neonatal microbiota (**Figs 4B – D**).
257 Though all IgG subclasses were detectable in breastmilk, the IgG response to pup-derived
258 microbiota in both milk and serum was largely composed of IgG2b and IgG3 subclasses (**Fig 4E,**
259 **S8C**), consistent with our previous report using serum and microbiota from adult animals (13).
260 When matched for concentration, milk IgG tended to bind a larger fraction of infant gut bacteria,
261 while paired serum IgG bound a larger proportion of bacteria derived from 3-month-old μ MT^{-/-}
262 adult mice (**Fig S8D**). Additionally, we confirmed that fractionated IgG used for feeding studies
263 retained the ability to bind to neonatal gut microbes (**Fig S8E**).

264
265 We queried whether efficient binding to intestinal microbes was required for oral IgG to
266 prevent neonatal mucosal immune dysregulation. Using serum IgG from germ-free mice (GF-
267 sIgG), which harbor reduced titers of microbiota-reactive antibodies, including to the infant
268 microbiota (**Fig 4F** (13, 48)), we fed progeny of μ MT^{-/-} dams and B6 sires 1 μ g/day GF-sIgG, SPF-
269 sIgG, or BSA between p0-7. Though normalized by concentration, GF-sIgG was unable to restrain
270 mucosal immune dysregulation, as evidenced by the heightened mLN Tfh responses in these
271 animals compared to pups fed SPF-sIgG (**Figs 4G, Fig S8F**).

272
273 Since IgG from germ-free mice retained some ability to bind the microbiota, it is possible
274 that higher amounts of GF sIgG would be sufficient to limit subsequent T cell responses. Thus,
275 we attempted complementary experiments by administering commercially available ‘non-specific’
276 monoclonal antibodies. We identified IgG1 and IgG2a (allelic variant of IgG2c) clones that did not
277 react to the infant microbiota; however, all IgG2b and IgG3 clones we tested exhibited some
278 amount of binding (**Fig S8G**). The commensal-reactive IgG antibody response is largely
279 comprised of IgG2b and IgG3 responses (**Fig 4E**). As IgG subclass composition is a core
280 determinant of antibody function (49, 50), we opted to administer a cocktail of IgG antibodies
281 containing non-specific IgG1 and IgG2a as well as IgG2b and IgG3 clones that demonstrated low
282 microbiota binding. Compared with mice given sIgG, mucosal Tfh responses tended to be higher
283 in pups given the IgG isotype cocktail; yet this difference was not statistically significant (**Fig S8**
284 **H, I**). This partial effect could be ascribed to the non-negligible, microbiota binding by IgG2b and

285 IgG3 antibodies in the cocktail. Nevertheless, the equivalent immune dysregulation in offspring
286 administered BSA or the isotype cocktail suggested that antigen binding in the postnatal gut is
287 important for breastmilk IgG to shape mucosal T cell responses in offspring.

288 We investigated whether antibody-bacteria immune complexes were sufficient to prevent
289 immune dysregulation in pups that did not receive breastmilk antibodies. To recapitulate the
290 homeostatic T-independent, anti-commensal IgG responses observed in mice (13), we
291 immunized mice genetically deficient in all T cell subsets (TCR $\beta\delta^{-/-}$) with *E. coli* strain BL21
292 (BL21). While not substantially altering the distribution of serum IgG subclasses, immunization
293 elicited a modest increase in IgG1, IgG2c, and IgG2b and a substantial increase in IgG3 titers
294 (**Figs S9A, B**). Flow cytometry analysis of antibody binding to bacterial cells (bFLOW; (13, 51)
295 **Fig S9C**) revealed that the BL21-specific response was dominated by IgG2b and IgG3 isotypes,
296 which stably bound to BL21 for up to 1 week (**Figs S9D, E**). Notably, immunization did not elicit
297 BL21-specific IgG1, whereas a slight IgG2c response was generated. Importantly, serum from
298 antibody-deficient μ MT $^{-/-}$ and naive TCR $\beta\delta^{-/-}$ mice exhibited similar IgG binding profiles,
299 demonstrating that naïve TCR $\beta\delta^{-/-}$ mice in our colony did not harbor 'natural' IgG capable of
300 binding this strain (**Figs S9D, E**).

301 Like administration of slgG, feeding pups BL21 coated or 'complexed' with IgG from
302 immune mice (Immune-BL21) during the first week of life reduced mucosal Tfh responses in
303 maternal antibody-deficient offspring at p25 (**Figs 4H, I and Fig S9F**). In contrast, Tfh numbers
304 and frequencies remained elevated in mice given BL21 incubated with sera from naïve mice
305 (naïve-BL21). As IgG from naïve TCR $\beta\delta^{-/-}$ mice did not bind to BL21 (**Figs S9D, E**), these data
306 indicated that early life encounter of IgG-bacteria immune complexes was sufficient to restrain T
307 cell immune dysregulation following weaning. Mucosal Tfh responses tended to be lower in pups
308 given polyclonal slgG compared to those given BL21-IgG immune complexes, perhaps reflecting
309 that breastmilk IgG must bind multiple types of infant gut bacteria to maximally dampen immune
310 dysregulation (**Figs 4I and Fig S9F**). Collectively, these data indicate that maternal IgG binds to
311 and forms immune complexes with microbes in the infant gut to tune neonatal immunity.

312 ***Maternal IgG engages neonatal IgG sensors to restrain microbiota-dependent adaptive*** 313 ***immunity.***

314 The Fc domain of mouse IgG immune complexes allows them to shape immune
315 responses by triggering IgG-sensing systems, including binding Fc receptors (FcRs) and
316 activating complement (52). Analysis of wild-type pups at p6 revealed broad expression of FcRs
317 and complement receptors by gut myeloid cells (**Figs 5A, S10A – D**). To define the molecular
318 basis by which maternal IgG restrained neonatal immune dysregulation, we fostered FcR $\gamma^{-/-}$
319 offspring, which lack the common FcR γ chain required for the expression and signaling of
320 activating FcRs (Fc γ RI, Fc γ RIII, and Fc γ RIV (53)), to antibody-deficient μ MT $^{-/-}$ dams at p0 and fed
321 them slgG or BSA daily for the first week of life (**Fig 5B**). Administration of slgG decreased mLN
322 Tfh frequency and trended toward reduced numbers in p25 FcR $\gamma^{-/-}$ offspring (**Figs 5C, S10E**). IgG
323 also activates complement via C1q, and oral administration of slgG triggered elevated intestinal
324 C5a levels, a downstream product of complement activation, in infant mice in a C1q-dependent
325 manner (**Fig S10F**). However, slgG was able to attenuate mLN Tfh responses in offspring lacking
326 this pathway (C1qa $^{-/-}$ pups; **Figs 5D, S10G**).

327 Since neither IgG-sensing pathway in isolation was necessary for maternal IgG to restrain
328 mucosal Tfh responses, we generated C1qa $^{-/-}$ FcR $\gamma^{-/-}$ mice lacking both pathways. IgG
329 administration to C1qa $^{-/-}$ FcR $\gamma^{-/-}$ offspring fostered to lactating μ MT $^{-/-}$ dams was unable to prevent
330 adaptive immune dysregulation in these animals, which phenocopied control μ MT $^{-/-}$ -born offspring
331 that did not receive IgG (**Figs 5E, S10H**). Thus, IgG sensing by the neonatal immune system was
332 required for maternal IgG to calibrate offspring mucosal immunity.
333
334

335 **Early life acquisition of oral IgG broadly regulates infant gut immunity following weaning**

336 The temporal difference between maternal IgG activity, required in the first week of life,
337 and subsequent impact on mucosal immunity following weaning suggested a regulatory
338 mechanism whereby early postnatal immune engagement by maternal IgG served to temper later
339 responses to gut antigens. Consistent with this model, we found that the provision of oral IgG in
340 early life protected mice from experimental colitis induced during the weaning transition.
341 Compared with BSA-treated littermates, slgG supplementation of progeny of μ MT^{-/-} dams and B6
342 sires resulted in greater weight gain, longer colon lengths, and reduced inflammatory cytokine
343 levels induced by oral administration of Dextran Sodium Sulfate (DSS) (**Figs S11A – C**).

344 To further explore this idea of immune instruction, we assessed whether maternal IgG
345 regulated infant adaptive immune responses to newly encountered food antigens using a well-
346 established protocol of dietary ovalbumin (OVA) administration (54, 55). During the first week of
347 life, we fed maternal antibody-deficient offspring BSA or purified slgG isolated from naïve mice
348 that did not harbor OVA-reactive IgG (**Fig S11D**). At weaning, we adoptively transferred naïve
349 OVA-specific CD4 T cells into neonates and fed them dietary OVA (**Fig 5F**). Analysis one week
350 later revealed the expected increase in OVA-specific Foxp3⁺ Treg cells in the mLN of mice given
351 dietary OVA. This expansion did not differ between pups given IgG or BSA, indicating that the
352 absence of maternal antibodies did not impair peripheral Treg induction to food antigens (**Figs**
353 **5G, S11E, F** and (55)). Food antigens have been shown to elicit the differentiation of a small
354 subset of Tfh cells, as well as a distinct population of FR4⁺CD73⁺CD44^{hi} activated cells that lack
355 expression of other key transcription factors such as ROR γ t and T-bet (termed Th^{lin-} (56)). We
356 observed an increased accumulation of OVA-specific Tfh cells, and a concomitant decrease in
357 Th^{lin-} cells in the mLN of OVA-treated pups that did not receive IgG (**Figs 5H – J, S11G, H**).
358 Elevated food-specific Tfh responses also correlated with an increase in intestinal titers of OVA-
359 specific IgE, a key Tfh-dependent mediator of allergic disease, as well as circulating OVA-specific
360 IgG1 titers (**Figs 5K, S11I**). These data demonstrated that oral acquisition of maternal IgG in the
361 first week of life dampens the differentiation of Tfh cell and associated IgE responses to food
362 antigens. As the IgG fed to pups did not bind the dietary antigen used in this model, our results
363 indicated that ingestion of microbiota-reactive, maternal IgG broadly shapes infant adaptive
364 immune responses to newly encountered mucosal antigens during the weaning transition.

365

366 **Discussion**

367 Breastmilk antibodies are critical for establishing intestinal homeostasis, yet the
368 mechanisms underlying this process remain elusive. Here, we demonstrated that neonatal
369 sensing of breastmilk IgG-microbiota immune complexes in early postnatal life was sufficient to
370 guide subsequent mucosal immune responses following weaning, including dampening Tfh
371 responses to microbiota-derived and dietary antigens and alleviating disease severity during
372 experimental colitis. As our work focused on early life, how breastmilk IgG influences long-term
373 health outcomes remains an open question. Nevertheless, our discovery of a temporal difference
374 between maternal IgG activity in the first week of life and the subsequent impact on intestinal
375 immunity following weaning provides a regulatory mechanism compatible with dynamic and
376 sometimes unpredictable changes in microbiota assembly and food antigen exposure typical of
377 the weaning transition (57-59).

378 The immunoregulatory activity of oral IgG correlated with binding to the infant microbiota.
379 IgG with reduced reactivity to gut microbes failed to completely restrain immune dysregulation,
380 suggesting that microbial recognition is essential. However, future studies using truly non-
381 microbiota-reactive IgG are warranted to confirm this result. Though the milk- and serum-purified
382 IgG used in our studies contained all IgG subclasses, the murine commensal-reactive IgG
383 response is largely composed of IgG2b and IgG3 subclasses (13, 48). It is possible that these
384 isotypes are required for breastmilk IgG to dampen immunity, an idea supported by the reduced

385 mLN Tfh responses observed in offspring fed *E. coli* primarily coated with IgG2b and IgG3. Prior
386 work has indicated that the transfer of maternal IgG1-food antigen complexes via breastfeeding
387 induce food antigen-specific Treg cells and protect offspring from allergic disease (60). Whether
388 IgG binding to dietary antigens (i.e., food-IgG complexes) can also broadly limit mucosal T cell
389 responses to other microbiota and dietary-derived antigens remains unknown.

390 Although maternal IgA also binds offspring microbiota, milk IgA did not restrain adaptive
391 immune responses in maternal antibody-deficient offspring as effectively as IgG. This result may
392 reflect differences in necessary concentration or in microbial targeting breadth, as IgG can target
393 a more expansive proportion of the microbiota compared to IgA (13). Additionally, the
394 engagement of IgG-sensing systems in offspring, including activating Fc receptors and
395 complement components, further distinguishes oral IgG from other isotypes abundant in milk.
396 Though activating Fc γ R_s do not bind IgA or IgM, IgM effectively triggers complement. However,
397 previous work indicates that milk IgM alone is unable to prevent mucosal immune dysregulation
398 in murine offspring (13). Engagement of IgG sensing systems provides contextual cues to APCs
399 that guide diverse downstream effects such as increasing phagocytosis, expression of
400 costimulatory molecules, and antigen presentation to T cells (52, 61, 62). Considering the breadth
401 of Fc γ R and complement receptor expression by infant gut myeloid populations, future studies
402 investigating how breastmilk IgG shapes the function of these cells to regulate T-dependent
403 mucosal immunity are warranted.

404 While our feeding approach demonstrated that IgG was sufficient to attenuate immune
405 activation in maternal antibody-deficient pups, our findings do not preclude contributions from
406 other milk isotypes in regulating host-microbiota interactions in the natural setting. Breastmilk IgA
407 can facilitate postnatal microbiota assembly, support intestinal epithelial cell function, and limit
408 microbial translocation and immune activation (16, 27, 47, 63, 64). IgM, though less studied, may
409 augment complement-mediated lysis of milk bacteria, thus shaping the composition of microbes
410 that seed the infant gut (65). Coupled with our work, these observations suggest that breastmilk
411 antibody isotypes operate through distinct, yet potentially complementary, mechanisms to
412 establish intestinal homeostasis.

413 IgG is also readily detectable in human breastmilk (66, 67), albeit at substantially lower
414 concentrations than in mice. Despite this low abundance, several reports have described
415 functions of human milk IgG in regulating infant immunity at both mucosal and systemic sites (22,
416 68-70). Like mice, healthy humans generate circulating microbiota-reactive IgG antibodies (66,
417 67); yet their transfer via breastfeeding and function in guiding mucosal immunity remain
418 unknown. Moreover, humans encode a receptor for IgA (Fc alpha receptor; Fc α R1 (71)), which
419 may allow breastmilk IgA to promote intestinal homeostasis via mechanisms parallel to those of
420 mouse IgG. Dissecting the specific features of breastmilk, microbiota-reactive IgG that contribute
421 to immune instruction – and how these features differ from other antibody isotypes and across
422 species – remain important areas of investigation.

423 Although our work centers on T-dependent responses to dietary antigens and the
424 microbiota, breastmilk IgG may also restrain responses to other gut antigens acquired in early
425 life, including vaccines or enteric pathogens (72). Mucosal Tfh cells and associated GC-derived
426 antibodies can shape microbiota composition and function, cross-react with enteric pathogens
427 and dietary antigens, and influence pathological responses in the contexts of barrier breach,
428 cancer, and inflammatory disease (24, 64, 73-75). Notably, a substantial proportion of the adult
429 intestinal B cell pool in mice originates from precursors activated during the weaning period,
430 suggesting that perturbations to B cell responses during this window could have durable impacts
431 (76). The exaggerated Tfh and GC responses in mice not receiving oral IgG could serve as a
432 compensatory mechanism to restore intestinal homeostasis or, conversely, contribute to adverse
433 health outcomes in certain contexts. For instance, heightened generation of food-specific IgE in
434 the absence of oral IgG could increase susceptibility to allergic diseases among non-breastfed
435 individuals (77, 78).

436 Our findings reveal a function of maternal IgG in directing tolerogenic mucosal immunity
437 responses through neonatal recognition of IgG-microbe immune complexes, expanding the scope
438 of maternal IgG beyond its traditional function in providing passive defense to infants against
439 virulent microorganisms (23). Further understanding the maternal-offspring interactions that
440 shape immune education will advance strategies to promote beneficial responses to innocuous
441 microbes and environmental antigens and prevent pathological responses throughout life.
442

443

444 Materials and Methods

445 *Mice* Specific pathogen-free (SPF) C57Bl/6J (Jax000664), μ MT^{-/-} (B6.129S2-*Ighm*^{tm1Cgn}/J,
446 Jax002288), *C1qa*^{-/-} (B6(Cg)-*C1qa*^{tm1d(EUCOMM)Wtsi}/TennJ, Jax031675), and TCR $\beta\delta$ ^{-/-}, (B6.129P2-
447 *Tcrb*^{tm1Mom} *Tcrd*^{tm1Mom}/J, Jax002122) mice were purchased from the Jackson Laboratory. Jh^{-/-} mice
448 on the Balb/c background were purchased from Taconic (1147). *Fcrg*^{-/-} mice generated using
449 C57Bl/6 embryonic stem cells by Dr. Takashi Saito were obtained from a material transfer
450 agreement (RIKEN). Germ-free C57Bl/6 mice were purchased from Taconic (Tac-B6) and germ-
451 free and SPF colonized C57Bl/6 Jh^{-/-} mice were provided by Dr. Andrew Macpherson (Bern,
452 Switzerland).

453 All mice were bred and maintained at an American Association for the Accreditation of Laboratory
454 Animal Care (AAALAC)-accredited animal facility at the Fred Hutchinson Cancer Center (SPF
455 animals) or UC Berkeley (germ-free animals) and housed in accordance with the procedures
456 outlined in the *Guide for the Care and Use of Laboratory Animals*. All experiments with mice were
457 performed in accordance with the guidelines of the Institutional Animal Care and Use Committee
458 at the Fred Hutchinson Cancer Center (protocol # 51030) or UC Berkeley (protocol # 2015-02-
459 7222-3). All mice were maintained under a 12-h light-dark cycle (7 a.m. to 7 p.m.) and given a
460 standard chow diet (Teklad 2918) and neutral water (pH 6.5-7.5) *ad libitum* unless otherwise
461 indicated.

462 For cohousing experiments, mice were combined at 3–4 weeks of age until breeding age. For
463 breeding of littermate or cohoused dams, females were separated into individual cages and bred
464 for 2–3 nights. Dams were then “re-cohoused” for approximately 18 days. Pregnant females were
465 separated and housed individually until parturition. Age-matched offspring of both sexes were
466 used in experiments. In some cases, pups were tattooed at birth using a 25G needle (Ketchum).

467 *Tissue processing*

468 Mice were euthanized with CO₂, and the mLN and PP were collected and placed into 0.5mL cold
469 complete media (RPMI 1640 supplemented with 2mM L-glutamine, 1mM sodium pyruvate,
470 100U/ml penicillin, 100mg/mL streptomycin; all from Gibco) supplemented with 5% or 3% (v/v)
471 Fetal Calf Serum (FCS; Cytiva) in a 6 well plate. Lymphoid tissues were digested by adding 5mL
472 complete media (without FCS) containing 0.5mg/mL DNaseI (Sigma-Aldrich) and 1mg/mL
473 Collagenase III (Stem Cell Technologies) to each well and incubating plates for 20-30min at 37°C.
474 Small intestinal tissues were cut into 1inch pieces, placed into 5mM EDTA (Sigma-Aldrich) with
475 0.15mg/mL DTT (Sigma-Aldrich) in complete media, and stirred at 37°C. Small intestine tissue
476 suspensions were strained through kitchen strainers (Amazon.com) and shaken for 30 seconds
477 by hand in 5mM EDTA in complete media three times to remove epithelial cells, then digested by
478 incubating tissues with 0.5mg/mL DNaseI and 0.2 mg/mL Liberase Blendzyme TL (Millipore
479 Sigma) for 30min at 37°C. The enzymatic reaction was stopped with the addition of 10 ml cold
480 complete media containing 3% FCS and tissues were passed through 70 μ m (mLN, small
481 intestine) or 100 μ m (PP) cell strainers. The rubber end of 1mL syringe plungers were used to
482 gently mash remaining tissue pieces through the filter, after which the filter was rinsed with

483 complete media to enhance cell recovery. Cells were pelleted at 475xg, the supernatant was
484 aspirated, and the pellet was resuspended in complete media containing 3% FCS prior to
485 downstream analysis. The pellet from small intestine prep was resuspended in 37.5% Percoll
486 (Cytivia), centrifuged at 690xg for 20 min without brake. The cell pellet was washed once in
487 complete media containing 3% FCS, cells were then pelleted at 475xg, the supernatant was
488 aspirated, and the pellet was resuspended in complete media containing 3% FCS prior to
489 downstream analysis.

490 *Flow cytometry*

491 For microbiota flow cytometry, intestinal contents were dissected out, placed in 1mL sterile PBS
492 in a microfuge tube and vortexed vigorously. Contents were centrifuged at 200xg and supernatant
493 containing bacteria transferred to a separate microfuge. Bacteria were pelleted at 3210xg, rinsed
494 with sterile PBS, pelleted again at 3210xg and OD₆₀₀ was measured. Bacteria were resuspended
495 at approximately 5×10^7 bacteria/mL in sterile-filtered Bacterial Staining Buffer (BSB; PBS
496 with 1% bovine serum albumin (BSA; Fisher) and 0.05% sodium azide (Sigma-Aldrich)). Bacterial
497 concentration was estimated as an OD of 1 = 5×10^8 bacteria/mL. 25 μ L of diluted serum or
498 breastmilk antibodies was mixed with 25 μ L microbial suspension in a v-bottom plate and
499 incubated for 30min at 4°C. 100 μ L of BSB was added to each well, and cells were pelleted by
500 centrifugation at 3210g for 5min. Secondary staining with fluorochrome-conjugated or biotinylated
501 antibodies diluted in BSB followed by streptavidin-PE-Cy7 diluted in BSB was performed (20min
502 each at 4°C). Cells were centrifuged at 3210g for 5min and resuspended in sterile-filtered PBS
503 with SYBR Green (Invitrogen) and analyzed by FACS. A similar protocol was used for bacterial
504 flow cytometry, except that an overnight culture of *E. coli* (BL21) was used as a source of
505 microbes, rather than intestinal contents, and resuspended at 10×10^6 /mL., then plated at $2.5 \times$
506 10^5 / well. See **Table S1** for a list of antibody clones/dyes and concentrations used.

507 For flow cytometry of leukocytes, approximately $2-5 \times 10^6$ cells were incubated in 40 μ L of fixable
508 viability dye (Tonbo Biosciences) diluted in PBS. This and all subsequent steps were performed
509 in the dark at room temperature unless otherwise stated. After 15 minutes, 10 μ L of Fc block diluted
510 in FACS buffer (PBS supplemented with 2% (v/v) FCS and 2mM EDTA; Sigma-Aldrich) was
511 added to cells. After 5 minutes, 50 μ L of the extracellular antibody stain diluted in FACS buffer was
512 added. After 30min, 100 μ L FACS buffer was added to each well, cells were centrifuged at 475g
513 for 5min, and fixed and permeabilized using the Foxp3/Transcription Factor Staining Buffer Set
514 (ThermoFisher Scientific) for 20min at 4°C. Cells were centrifuged at 685g for 5min, and 100 μ L of
515 the intracellular antibody stain diluted in Perm Wash (ThermoFisher Scientific) was added. After
516 30-45min at 4°C, cells were washed with 150 μ L PermWash, centrifuged at 685g for 5min, and
517 resuspended in 200 μ L of PermWash. Analysis was performed no later than 18 hours post-staining
518 using a BD FACSymphony A5 High-Parameter Cell Analyzer. Beads (UltraComp eBeads,
519 Invitrogen) stained with individual antibodies were used for compensation, except for the viability
520 dye control, wherein compensation was performed with leftover cells incubated with the viability
521 dye alone. See **Table S1** for a list of antibody clones/dyes and concentrations used. To obtain
522 cell counts, a separate aliquot of cells was mixed with beads (Accucheck Counting Beads,
523 Invitrogen) and diluted in 4',6-Diamidino-2-Phenylindole (DAPI, Sigma Aldrich) and analyzed
524 immediately on a BD FACSymphony A5 High-Parameter Cell Analyzer or BD Canto. All data were
525 analyzed in FlowJo, version 10.

526 *Dietary OVA administration*

527 CD4⁺ T cells were isolated by magnetic bead separation (Miltenyi; L3T4). Mice were given $1-10 \times 10^5$
528 CD45.1 OTII CD4⁺ T cells via retro-orbital injection between p16-p18. The next day,
529 animals were given drinking water containing 1.5mg/mL OVA (grade III) until p25/26. For some
530 experiments, the day after OTII injection, 50 mg of OVA (grade III; A5378; Sigma) was

531 administered in 200 μ l PBS by oral gavage. Animals were harvested on p25/p26 or p40-45 for
532 analysis of T cell and antibody responses, respectively.

533

534 *DSS-induced colitis*

535 Offspring were cohoused at p20 and provided drinking water with 2% DSS (w/v) (molecular weight
536 36-50 kDa; Thermo-Fisher Scientific) for 7 days. Body weight and physical appearance were
537 monitored approximately every other day until time of sacrifice. Mice that appeared moribund or
538 experienced \geq 25% weight loss were euthanized.

539 *Measurement of Intestinal Permeability*

540 Mice were given 100mg/kg FITC-dextran (4kDa or 150kDa, Sigma), 10mg/kg monoclonal IgG2b
541 (Bioxcel), or 5mg/kg monoclonal ReadyTag anti-ova IgG1 (Bioxcell) diluted in PBS via pipet
542 feeding (p0-13) or oral gavage (p14-18). As a positive control, some animals were given
543 substances i.v. 2 hours later, blood was isolated by decapitation (p0-10) or cardiac puncture (p10-
544 28) and allowed to clot for 15min at room temperature. Samples were centrifuged at 13,000g for
545 15min and serum collected. For FITC-dextran, serum was diluted 1:5 in PBS and measured with
546 excitation and emission wavelengths of 435 and 538nm, respectively, using an Epoch microplate
547 reader (Biotek). Serum IgG2b and anti-OVA IgG1 titers were assessed via ELISA. Fluorescence
548 or antibody levels were interpolated from a standard curve generated via nonlinear 4 parametric
549 logistic regression (Prism, GraphPad).

550 For bacterial gavage experiments, mice were administered $1-10 \times 10^{10}$ *E.coli* K12 MG155
551 containing a plasmid encoding for ampicillin resistance (pTrc-HisC; Invitrogen #V36020) in 150 μ L
552 PBS via oral gavage at p21. Mice were gavaged with metal animal feeding needles, 22 gauge, 1"
553 (Cadence Scientific). *E. coli* K12 cultures were grown overnight in Luria-Bertani (LB) broth
554 (Research Products International) at 37°C, cultures were centrifuged at 4000xg and washed with
555 PBS twice, and OD was attained by spectrophotometer. OD600 = 1.0 was estimated as 1×10^8
556 bacteria/mL and cfu was confirmed by plate count. 16-18 hours post-gavage, animals were
557 euthanized, mLN collected into 2mL microtubes containing 0.5mL PBS, and homogenized
558 (Polytron). 250 μ L of homogenate was plated on LB agar per mouse, plates were incubated at
559 37°C, and colonies were counted 18-36 hours later. Plate counts were multiplied by 2 to estimate
560 cfu/mL.

561 *Mouse antibody feeding experiments*

562 Pups were fed daily between p0-p7 (8 days) of life with up to 10 μ g purified antibodies diluted in
563 PBS, with the exception of the IgG titration feed (Fig 2G, Fig S4F). Pups were administered up to
564 2 μ l of diluted antibodies per day via pipet. For isotype cocktail experiments (Fig S8F-H), each pup
565 was given a cocktail comprised of 1 μ g of IgG1 (BioXcell, RT0267), 5 μ g of IgG2a (BioXcell,
566 BP0085), 3 μ g of IgG2b (Sydlabs, PA007130), and 1 μ g of IgG3 (Biolegend, 401329), reflecting
567 the distribution of subclasses observed in Protein A-purified slgG (i.e, 10%IgG1, 50%IgG2b,
568 30%IgG2a/c, 10%IgG3 as per Fig 2D).

569 *Enzyme-linked immunosorbent assay (ELISA)*

570 Approximately 3 cm of the terminal ileum was homogenized at 100 mg/mL in PBS containing
571 protease inhibitor (Roche). Serum, milk, or homogenized ileal tissue was centrifuged 13,000g for
572 10min and supernatant was used to assay immunoglobulin levels or complement proteins by
573 ELISA. Briefly, Nunc Hi Affinity ELISA plates (Thermo Scientific) were coated with isotype-specific
574 antibodies or 50 μ g/ml OVA (grade VI, Sigma A2512) overnight at 4°C or C5a coating antibody
575 overnight at room temperature. C5a ELISA was performed by following the manufacturer
576 instructions (Biotechne DY2150) using Duoset reagents kit (DY008B). For isotype and OVA-
577 specific ELISA, plates were washed 5X with Wash Buffer (PBS containing 1%BSA (w/v; Fisher)

578 and 0.05% Tween-20 (v/v; Fisher)) and blocked with PBS with 1% BSA (w/v) and 2% goat serum
579 diluted in PBS (Gibco; v/v) for 1 hour at 22-25°C. Plates were washed 5X with Wash Buffer, serial
580 dilutions of samples diluted in PBS with 1% BSA were added, and plates were incubated for up
581 to 2hr at 22-25°C. Plates were washed 5X with Wash Buffer and peroxidase-conjugated
582 secondary antibodies specific to mouse isotypes and diluted in PBS containing 1% BSA were
583 added. After up to 2hr at 22-25°C, plates were washed 5X with Wash Buffer, and developed using
584 1-Step Turbo TMB (Thermo Fisher) followed by 2N H₂SO₄ Stop solution. Absorbance at 450nm
585 was measured on an Epoch microplate reader (Biotek) within 10min of adding Stop solution. See
586 **Table S1** for a list of antibody clones and concentrations used. Antibody titers were interpolated
587 from a standard curve generated via nonlinear 4 parametric logistic regression (Prism,
588 GraphPad).

589 *IL-22 Detection*

590 Approximately 3cm of the terminal ileum was homogenized at 100 mg/mL in PBS containing
591 protease inhibitor (Roche). Homogenate was centrifuged at 13,000g for 10min and supernatant
592 was used to assay IL-22 levels via Bio-Plex Mouse IL-22 kit (Biorad) according to the
593 manufacturer's instructions.

594 *Antibody purification from serum and milk*

595 For milk collection, dams were separated from pups for 2 hours at 3 -18 days post-parturition and
596 anesthetized via nose-cone with isoflurane. Dams were injected intraperitoneally with 250uL of 2
597 IU oxytocin diluted in 1mL PBS (Thermo-Fisher Scientific), and milk expression was encouraged
598 with hand massage. Milk was collected using microhematocrit capillary tubes, transferred to a
599 microfuge tube and stored at -80°C for subsequent analysis.

600 For serum collection from adult mice, blood was collected via saphenous vein bleed or cardiac
601 puncture of mice at the time of euthanasia. For neonates, blood was collected after decapitation.
602 To collect serum, blood was allowed to clot at room temperature for up to 60min, centrifuged at
603 10°C, 13,000g for 15min, and the serum supernatant was transferred to a separate microfuge
604 tube and kept at -80°C for subsequent analysis.

605 Pooled serum or milk antibodies were purified over a Protein A column according to the
606 manufacturer's instructions with minor modifications as described below (Pierce; Thermo
607 Scientific). For milk antibodies, milk was thawed on ice, diluted 1:2 in PBS, centrifuged at 21,000g
608 for 15min, and the top (fat) layer was removed by aspiration. The milk supernatant was transferred
609 to a new tube, diluted a subsequent time 1:2 in PBS and centrifuged again at 21,000g for 15min.
610 The supernatant (minus fat layer) was used for Protein A fractionation. To ensure recovery of all
611 IgG isotypes, including IgG3, IgG was eluted via 2 sequential washes in Elution Buffer pH=2.8,
612 followed by 1 wash with Elution Buffer modified to pH=4.5. IgG was neutralized immediately
613 following each elution and all fractions were combined. IgG-enriched and -depleted protein
614 fractions were concentrated using a 100,000 MWCO protein concentrator (Pierce; Thermo
615 Scientific). Antibody purity and concentration were assessed by isotype and/or subclass specific
616 ELISA (e.g., IgA, IgG1, IgG2b, etc) and nanodrop protein absorption.

617 *Milk consumption*

618 Pups were fasted for 4 hours by separating them from lactating dams. Pups were then weighed,
619 returned to dams to nurse for one hour, and weighed a second time. Latching was confirmed by
620 visual confirmation and milk consumption was estimated by the difference in weight gain before
621 and after 1 hour of suckling. To maintain pup health and encourage suckling upon return to dam,
622 pups were kept on a heating pad during the fasting period and maintained in a darkened hood.
623 We note that as weight loss due to urination and defecation were not accounted for, reported
624 values may slightly underestimate total milk consumption.

625

626 *Antibiotic administration*

627 Microbiota depletion was performed as described (43). Briefly, animals were gavaged once per
628 day with a cocktail of antibiotics consisting of ampicillin (20mg/kg; Fisher), vancomycin (10mg/kg;
629 Sigma-Aldrich), neomycin (20mg/kg; ThermoFisher), and metronidazole (20mg/kg; Alfa Aesar)
630 between p17-24. Microbiota depletion was confirmed via stool culture on Luria-Bertani and blood
631 agar plates, as well as visual confirmation of enlarged cecums.

632 *Immune complex generation and administration*

633 Serum was collected from TCR β $\delta^{-/-}$ mice four weeks after i.v. injection of 1×10^6 *E.coli* (BL21,
634 Thermo Fisher Cat no. C600003) or PBS, and incubated with BL21 overnight at 4°C at a ratio of
635 1ul serum per 1.25×10^6 bacteria in 50 μ l PBS. Bacteria were washed in BSB to remove unbound
636 antibodies, resuspended at 5×10^6 cfu/ μ l, and kept at 4°C for 8 days. Immune complex formation
637 and stability was confirmed using bacterial flow cytometry on the first and last day of treatment.

638 Pups were fed daily between p0-p7 of life with 5×10^7 bacteria pre-incubated with sera from
639 immune or naïve animals.

640 *16S rRNA Gene Sequencing and Microbial Community Analysis*

641 Amplification and MiSeq Illumina Sequencing of the V4 region of the 16S gene was performed by
642 the Alkek Center for Metagenomics and Microbiome Research (CMMR) at Baylor College of
643 Medicine. Reads were demultiplexed, trimmed and quality checked with bbdduk (79). Paired-end
644 reads were then merged using bbmap (79) and run through the MaLiAmPi workflow to generate
645 Amplicon Sequence Variants (ASVs) using DADA2 (80, 81). The Bayesian classifier Pplacer (82)
646 was used to estimate taxonomic classification of ASVs using phylogenetic placement with a
647 likelihood cutoff of 90%. This analysis method does not use strict sequence similarity, which is
648 often not sufficient to distinguish between closely related reference sequences with differing
649 taxonomic assignments. Sequences that could not be assigned unambiguously to a single genus
650 were instead assigned at a higher taxonomic level. The degree of taxonomic resolution provided
651 by 16S amplicon sequencing is generally reported in the field at the genus level, with any lower-
652 level results (i.e. species) generally viewed with a level of skepticism. This conservative approach
653 led us to report genus level results in our analysis.

654 Alpha diversity estimates were generated by MaLiAmPi and Bray-Curtis dissimilarity was
655 calculated using the R package *vegan* (v2.6-4) (DOI:10.32614/CRAN.package.vegan (83)), to determine beta diversity estimates. A pseudocount
656 was applied prior to calculating differences in the relative abundance of taxonomic groups and
657 ASVs with fewer than 10 reads across all samples were removed from the dataset. Differential
658 abundance was determined using DESeq2 (84), and data was normalized using the “poscounts”
659 size estimator.

660 *Statistics*

661
662 Statistical significance was determined as indicated in the figure legends with Prism 10
663 (GraphPad Software Inc). Significance of beta diversity comparisons was determined using
664 PERMANOVA, which was conducted using the adonis2 function in the R package *vegan*.

665
666
667
668
669
670
671
672
673
674
675
676
677
678
679
680
681
682
683
684
685
686
687
688
689
690
691
692
693
694
695
696
697
698
699
700
701
702
703
704
705
706
707
708
709
710
711
712
713

References

1. Y. Belkaid, T. W. Hand, Role of the microbiota in immunity and inflammation. *Cell* **157**, 121-141 (2014).
2. D. Zheng, T. Liwinski, E. Elinav, Interaction between microbiota and immunity in health and disease. *Cell Res* **30**, 492-506 (2020).
3. J. L. Round, S. K. Mazmanian, The gut microbiota shapes intestinal immune responses during health and disease. *Nat Rev Immunol* **9**, 313-323 (2009).
4. L. M. Cox *et al.*, Altering the intestinal microbiota during a critical developmental window has lasting metabolic consequences. *Cell* **158**, 705-721 (2014).
5. M. P. Kronman, T. E. Zaoutis, K. Haynes, R. Feng, S. E. Coffin, Antibiotic exposure and IBD development among children: a population-based cohort study. *Pediatrics* **130**, e794-803 (2012).
6. T. Olszak *et al.*, Microbial exposure during early life has persistent effects on natural killer T cell function. *Science* **336**, 489-493 (2012).
7. K. A. Knoop *et al.*, Microbial antigen encounter during a preweaning interval is critical for tolerance to gut bacteria. *Sci Immunol* **2**, (2017).
8. J. Cahenzli, Y. Koller, M. Wyss, M. B. Geuking, K. D. McCoy, Intestinal microbial diversity during early-life colonization shapes long-term IgE levels. *Cell Host Microbe* **14**, 559-570 (2013).
9. K. P. Gopalakrishna, T. W. Hand, Influence of Maternal Milk on the Neonatal Intestinal Microbiome. *Nutrients* **12**, (2020).
10. J. D. Thai, K. E. Gregory, Bioactive Factors in Human Breast Milk Attenuate Intestinal Inflammation during Early Life. *Nutrients* **12**, (2020).
11. W. L. Hurley, P. K. Theil, Perspectives on immunoglobulins in colostrum and milk. *Nutrients* **3**, 442-474 (2011).
12. D. R. Kramer, J. J. Cebra, Early appearance of "natural" mucosal IgA responses and germinal centers in suckling mice developing in the absence of maternal antibodies. *J Immunol* **154**, 2051-2062 (1995).
13. M. A. Koch *et al.*, Maternal IgG and IgA Antibodies Dampen Mucosal T Helper Cell Responses in Early Life. *Cell* **165**, 827-841 (2016).
14. D. Ramanan *et al.*, An Immunologic Mode of Multigenerational Transmission Governs a Gut Treg Setpoint. *Cell* **181**, 1276-1290 e1213 (2020).
15. M. Gomez de Agüero *et al.*, The maternal microbiota drives early postnatal innate immune development. *Science* **351**, 1296-1302 (2016).
16. E. W. Rogier *et al.*, Secretory antibodies in breast milk promote long-term intestinal homeostasis by regulating the gut microbiota and host gene expression. *Proc Natl Acad Sci U S A* **111**, 3074-3079 (2014).
17. T. C. Cullender *et al.*, Innate and adaptive immunity interact to quench microbiome flagellar motility in the gut. *Cell Host Microbe* **14**, 571-581 (2013).
18. G. P. Donaldson *et al.*, Gut microbiota utilize immunoglobulin A for mucosal colonization. *Science* **360**, 795-800 (2018).
19. S. Okai *et al.*, High-affinity monoclonal IgA regulates gut microbiota and prevents colitis in mice. *Nat Microbiol* **1**, 16103 (2016).
20. O. Pabst, V. Cerovic, M. Hornef, Secretory IgA in the Coordination of Establishment and Maintenance of the Microbiota. *Trends Immunol* **37**, 287-296 (2016).
21. T. Rollenske *et al.*, Parallelism of intestinal secretory IgA shapes functional microbial fitness. *Nature* **598**, 657-661 (2021).
22. C. Atyeo, G. Alter, The multifaceted roles of breast milk antibodies. *Cell* **184**, 1486-1499 (2021).

- 714 23. S. N. Langel, M. Blasi, S. R. Permar, Maternal immune protection against infectious
715 diseases. *Cell Host Microbe* **30**, 660-674 (2022).
- 716 24. J. J. Bunker, A. Bendelac, IgA Responses to Microbiota. *Immunity* **49**, 211-224 (2018).
- 717 25. Y. Yang, N. W. Palm, Immunoglobulin A and the microbiome. *Curr Opin Microbiol* **56**, 89-
718 96 (2020).
- 719 26. H. Renz *et al.*, The neonatal window of opportunity-early priming for life. *J Allergy Clin*
720 *Immunol* **141**, 1212-1214 (2018).
- 721 27. K. P. Gopalakrishna *et al.*, Maternal IgA protects against the development of necrotizing
722 enterocolitis in preterm infants. *Nat Med* **25**, 1110-1115 (2019).
- 723 28. A. C. Ericsson, C. L. Franklin, The gut microbiome of laboratory mice: considerations and
724 best practices for translational research. *Mamm Genome* **32**, 239-250 (2021).
- 725 29. C. A. Thomson, S. C. Morgan, C. Ohland, K. D. McCoy, From germ-free to wild:
726 modulating microbiome complexity to understand mucosal immunology. *Mucosal Immunol*
727 **15**, 1085-1094 (2022).
- 728 30. M. W. Hornef, N. Torow, 'Layered immunity' and the 'neonatal window of opportunity' -
729 timed succession of non-redundant phases to establish mucosal host-microbial
730 homeostasis after birth. *Immunology* **159**, 15-25 (2020).
- 731 31. K. D. McCoy, M. B. Geuking, F. Ronchi, Gut Microbiome Standardization in Control and
732 Experimental Mice. *Curr Protoc Immunol* **117**, 23 21 21-23 21 13 (2017).
- 733 32. T. Sun, A. Nguyen, J. L. Gommerman, Dendritic Cell Subsets in Intestinal Immunity and
734 Inflammation. *J Immunol* **204**, 1075-1083 (2020).
- 735 33. R. Kedmi, D. R. Littman, Antigen-presenting cells as specialized drivers of intestinal T cell
736 functions. *Immunity* **57**, 2269-2279 (2024).
- 737 34. T. Joeris, K. Muller-Luda, W. W. Agace, A. M. Mowat, Diversity and functions of intestinal
738 mononuclear phagocytes. *Mucosal Immunol* **10**, 845-864 (2017).
- 739 35. B. Mihi *et al.*, Interleukin-22 signaling attenuates necrotizing enterocolitis by promoting
740 epithelial cell regeneration. *Cell Rep Med* **2**, 100320 (2021).
- 741 36. C. S. Pohl, J. E. Medland, A. J. Moeser, Early-life stress origins of gastrointestinal disease:
742 animal models, intestinal pathophysiology, and translational implications. *Am J Physiol*
743 *Gastrointest Liver Physiol* **309**, G927-941 (2015).
- 744 37. C. Catassi, A. Bonucci, G. V. Coppa, A. Carlucci, P. L. Giorgi, Intestinal permeability
745 changes during the first month: effect of natural versus artificial feeding. *J Pediatr*
746 *Gastroenterol Nutr* **21**, 383-386 (1995).
- 747 38. S. S. Ogra, D. Weintraub, P. L. Ogra, Immunologic aspects of human colostrum and milk.
748 III. Fate and absorption of cellular and soluble components in the gastrointestinal tract of
749 the newborn. *J Immunol* **119**, 245-248 (1977).
- 750 39. S. Brajon *et al.*, All the Pups We Cannot See: Cannibalism Masks Perinatal Death in
751 Laboratory Mouse Breeding but Infanticide Is Rare. *Animals (Basel)* **11**, (2021).
- 752 40. M. Dorsch, I. Wittur, W. Garrels, Efficiency of timed pregnancies in C57BL/6 and BALB/c
753 mice by mating one male with up to four females. *Lab Anim*, 23677219897687 (2020).
- 754 41. C. Ohnmacht *et al.*, MUCOSAL IMMUNOLOGY. The microbiota regulates type 2 immunity
755 through RORgammat(+) T cells. *Science* **349**, 989-993 (2015).
- 756 42. E. Sefik *et al.*, MUCOSAL IMMUNOLOGY. Individual intestinal symbionts induce a distinct
757 population of RORgamma(+) regulatory T cells. *Science* **349**, 993-997 (2015).
- 758 43. D. H. Reikvam *et al.*, Depletion of murine intestinal microbiota: effects on gut mucosa and
759 epithelial gene expression. *PLoS One* **6**, e17996 (2011).
- 760 44. P. Ray, S. Chakraborty, A. Ghosh, P. Aich, Effects of treatment with three antibiotics,
761 vancomycin, neomycin, and AVNM on gut microbiome in C57BL/6 mice. *bioRxiv*,
762 2021.2002.2008.430372 (2021).
- 763 45. J. Fadlallah *et al.*, Microbial ecology perturbation in human IgA deficiency. *Sci Transl Med*
764 **10**, (2018).

- 765 46. K. Suzuki *et al.*, Aberrant expansion of segmented filamentous bacteria in IgA-deficient
766 gut. *Proc Natl Acad Sci U S A* **101**, 1981-1986 (2004).
- 767 47. A. M. Weis, J. L. Round, Microbiota-antibody interactions that regulate gut homeostasis.
768 *Cell Host Microbe* **29**, 334-346 (2021).
- 769 48. M. Y. Zeng *et al.*, Gut Microbiota-Induced Immunoglobulin G Controls Systemic Infection
770 by Symbiotic Bacteria and Pathogens. *Immunity* **44**, 647-658 (2016).
- 771 49. G. Vidarsson, G. Dekkers, T. Rispens, IgG subclasses and allotypes: from structure to
772 effector functions. *Front Immunol* **5**, 520 (2014).
- 773 50. P. Bruhns, F. Jonsson, Mouse and human FcR effector functions. *Immunol Rev* **268**, 25-
774 51 (2015).
- 775 51. K. Moor *et al.*, Analysis of bacterial-surface-specific antibodies in body fluids using
776 bacterial flow cytometry. *Nat Protoc* **11**, 1531-1553 (2016).
- 777 52. L. L. Lu, T. J. Suscovich, S. M. Fortune, G. Alter, Beyond binding: antibody effector
778 functions in infectious diseases. *Nat Rev Immunol* **18**, 46-61 (2018).
- 779 53. C. Ra, M. H. Jouvin, U. Blank, J. P. Kinet, A macrophage Fc gamma receptor and the
780 mast cell receptor for IgE share an identical subunit. *Nature* **341**, 752-754 (1989).
- 781 54. U. Hadis *et al.*, Intestinal tolerance requires gut homing and expansion of FoxP3+
782 regulatory T cells in the lamina propria. *Immunity* **34**, 237-246 (2011).
- 783 55. D. Mucida *et al.*, Oral tolerance in the absence of naturally occurring Tregs. *J Clin Invest*
784 **115**, 1923-1933 (2005).
- 785 56. S. W. Hong *et al.*, Immune tolerance of food is mediated by layers of CD4(+) T cell
786 dysfunction. *Nature* **607**, 762-768 (2022).
- 787 57. Z. Al Nabhani *et al.*, A Weaning Reaction to Microbiota Is Required for Resistance to
788 Immunopathologies in the Adult. *Immunity* **50**, 1276-1288 e1275 (2019).
- 789 58. T. Yatsunenکو *et al.*, Human gut microbiome viewed across age and geography. *Nature*
790 **486**, 222-227 (2012).
- 791 59. H. J. Ku, Y. T. Kim, J. H. Lee, Microbiome Study of Initial Gut Microbiota from Newborn
792 Infants to Children Reveals that Diet Determines Its Compositional Development. *J*
793 *Microbiol Biotechnol* **30**, 1067-1071 (2020).
- 794 60. A. Ohsaki *et al.*, Maternal IgG immune complexes induce food allergen-specific tolerance
795 in offspring. *J Exp Med* **215**, 91-113 (2018).
- 796 61. S. Bournazos, A. Gupta, J. V. Ravetch, The role of IgG Fc receptors in antibody-dependent
797 enhancement. *Nat Rev Immunol* **20**, 633-643 (2020).
- 798 62. E. E. West, M. Kolev, C. Kemper, Complement and the Regulation of T Cell Responses.
799 *Annu Rev Immunol* **36**, 309-338 (2018).
- 800 63. G. P. Donaldson *et al.*, Suppression of epithelial proliferation and tumorigenesis by
801 immunoglobulin A. *bioRxiv*, 2023.2010.2006.561290 (2023).
- 802 64. O. Pabst, E. Slack, IgA and the intestinal microbiota: the importance of being specific.
803 *Mucosal Immunol* **13**, 12-21 (2020).
- 804 65. D. Xu *et al.*, Complement in breast milk modifies offspring gut microbiota to promote infant
805 health. *Cell* **187**, 750-763 e720 (2024).
- 806 66. H. Akhter, F. Aziz, F. R. Ullah, M. Ahsan, S. N. Islam, Immunoglobulins content in
807 colostrum, transitional and mature milk of Bangladeshi mothers: Influence of parity and
808 sociodemographic characteristics. *J Mother Child* **24**, 8-15 (2020).
- 809 67. M. Czosnykowska-Lukacka, J. Lis-Kuberka, B. Krolak-Olejnik, M. Orczyk-Pawilowicz,
810 Changes in Human Milk Immunoglobulin Profile During Prolonged Lactation. *Front Pediatr*
811 **8**, 428 (2020).
- 812 68. N. I. Mazur *et al.*, Breast Milk Prefusion Fc Immunoglobulin G as a Correlate of Protection
813 Against Respiratory Syncytial Virus Acute Respiratory Illness. *J Infect Dis* **219**, 59-67
814 (2019).

- 815 69. J. Mabuka, R. Nduati, K. Odem-Davis, D. Peterson, J. Overbaugh, HIV-specific antibodies
816 capable of ADCC are common in breastmilk and are associated with reduced risk of
817 transmission in women with high viral loads. *PLoS Pathog* **8**, e1002739 (2012).
- 818 70. G. G. Fouda *et al.*, HIV-specific functional antibody responses in breast milk mirror those
819 in plasma and are primarily mediated by IgG antibodies. *J Virol* **85**, 9555-9567 (2011).
- 820 71. R. C. Monteiro, J. G. Van De Winkel, IgA Fc receptors. *Annu Rev Immunol* **21**, 177-204
821 (2003).
- 822 72. P. L. F. Rippey, F. Aravena, J. P. Nyongator, Health Impacts of Early Complementary Food
823 Introduction Between Formula-fed and Breastfed Infants. *J Pediatr Gastroenterol Nutr* **70**,
824 375-380 (2020).
- 825 73. D. Sterlin, J. Fadlallah, E. Slack, G. Gorochoy, The antibody/microbiota interface in health
826 and disease. *Mucosal Immunol* **13**, 3-11 (2020).
- 827 74. K. E. Huus, C. Petersen, B. B. Finlay, Diversity and dynamism of IgA-microbiota
828 interactions. *Nat Rev Immunol*, (2021).
- 829 75. K. Chen, G. Magri, E. K. Grasset, A. Cerutti, Rethinking mucosal antibody responses: IgM,
830 IgG and IgD join IgA. *Nat Rev Immunol* **20**, 427-441 (2020).
- 831 76. S. Vergani *et al.*, A self-sustaining layer of early-life-origin B cells drives steady-state IgA
832 responses in the adult gut. *Immunity* **55**, 1829-1842 e1826 (2022).
- 833 77. Z. Koukou *et al.*, The Effect of Breastfeeding on Food Allergies in Newborns and Infants.
834 *Children (Basel)* **10**, (2023).
- 835 78. A. Stuebe, The risks of not breastfeeding for mothers and infants. *Rev Obstet Gynecol* **2**,
836 222-231 (2009).
- 837 79. B. Bushnell, J. Rood, E. Singer, BBMerge - Accurate paired shotgun read merging via
838 overlap. *PLoS One* **12**, e0185056 (2017).
- 839 80. S. S. Minot *et al.*, MaLiAmPi enables generalizable and taxonomy-independent
840 microbiome features from technically diverse 16S-based microbiome studies. *Cell Rep*
841 *Methods* **3**, 100639 (2023).
- 842 81. B. J. Callahan *et al.*, DADA2: High-resolution sample inference from Illumina amplicon
843 data. *Nat Methods* **13**, 581-583 (2016).
- 844 82. F. A. Matsen, R. B. Kodner, E. V. Armbrust, pplacer: linear time maximum-likelihood and
845 Bayesian phylogenetic placement of sequences onto a fixed reference tree. *BMC*
846 *Bioinformatics* **11**, 538 (2010).
- 847 83. Jari Oksanen *et al.*, Vegan: Community Ecology Package, [https://cran.r-](https://cran.r-project.org/package=vegan)
848 [project.org/package=vegan](https://cran.r-project.org/package=vegan). (2025).
- 849 84. M. I. Love, W. Huber, S. Anders, Moderated estimation of fold change and dispersion for
850 RNA-seq data with DESeq2. *Genome Biol* **15**, 550 (2014).
- 851 85. M. K. Shenoy *et al.*, Breastmilk IgG engages the murine neonatal immune system to
852 instruct responses to gut antigens, dataset. *Dryad*, DOI: 10.5061/dryad.z8w9ghxrf (2025).
- 853
- 854

855 **Acknowledgements.**

856 We thank the Fred Hutch Comparative Medicine Facility, the Fred Hutch Flow Cytometry Core,
857 H. Wynd, L. Hueffed, N. Huber, and S. Minot for technical support. We thank G. Barton, G.
858 Reiner, A. Stanbery, and L. Kreuk, for providing germ-free sera and technical assistance
859 regarding germ-free experiments. We thank E. Tait-Wojno, O. Harrison, J. Talbot, and P.
860 Mitchell for critical reading of the manuscript. We thank Y. Wu, V. O'Brien, and M. Headley for
861 constructive feedback on this project. This research was supported by the Comparative
862 Medicine Shared Resource, RRID:SCR 022610 and the Flow Cytometry Shared Resource,
863 RRID:SCR 022613, of the Fred Hutch/University of Washington/Seattle Children's Cancer
864 Consortium (P30 CA015704). Some figure panels were created using BioRender, for which the
865 Koch Lab has been granted a license to publish in a journal.

866 **Funding:**

867 M.K.S was supported by the Fred Hutch Cancer Center's Immunotherapy Integrated Research
868 Center Award. H.T. and A.K.L are Washington Research Foundation Postdoctoral Fellows.
869 M.A.K. is a Pew Scholar in the Biomedical Sciences, supported by The Pew Charitable Trusts.
870 R01A1173199, and grants from the Hartwell Foundation, Rita Allen Foundation, Fred
871 Hutchinson Cancer Center's Microbiome Research Initiative Integrated Research Center and
872 the Kenneth Rainin Foundation to M.A.K. also supported this work. The content is solely the
873 responsibility of the authors and does not necessarily represent the official views of the National
874 Institutes of Health.

875

876 **Author contributions:**

877 Conceptualization: MKS, MAK

878 Formal Analysis: MKS, DMR, MAK

879 Methodology: MKS, MAK

880 Investigation: MKS, DMR, AKL, HT, SG, LJM, JSS, MEC, MAK

881 Visualization: MKS, DMR, MAK

882 Funding acquisition: MKS, MAK

883 Project administration: MKS, MAK

884 Writing – original draft: MKS, MAK

885 Writing – review & editing: MKS, AKL, HT, SG, JSS, MEC, MAK

886 **Competing Interests:** The authors declare that they have no competing interests.

887 **Data and Materials Availability:** All data needed to evaluate the conclusions in the paper are
888 present in the paper or the Supplementary Materials. 16S sequencing data are available on Dryad
889 (85). *Fcrg*^{-/-} mice are available from Dr. Takashi Saito under a material agreement with RIKEN.

890 **Supplementary Materials List**

891 Figures S1-S11

892 Table S1

893

894

895

896

897 Figure Legends

898 **Figure 1. Acquisition of breastmilk antibodies in early life prevents immune dysregulation**
899 **following weaning.** (A) (Top Schema) Timed breedings were performed using co-housed,
900 littermate $\mu\text{MT}^{+/-}$ and $\mu\text{MT}^{-/-}$ dams, and B6 sires. Offspring were maintained with their birth mother
901 or cross-fostered at postnatal day 0, 7, or 10, and analyzed at postnatal day 25 (p25). (Bottom)
902 Representative flow cytometric analysis of germinal center T follicular helper cells (GC Tfh cells,
903 $\text{CD4}^+\text{Foxp3}^-\text{CD44}^{\text{hi}}\text{PD-1}^+\text{CXCR5}^{\text{hi}}\text{Bcl6}^+$) isolated from the mesenteric lymph nodes (mLN) of p25
904 offspring born to and reared by the indicated dams. Numbers in flow plots indicate percentage of
905 Tfh cells of total CD4^+ T cells. Cells were gated according to the schematic in Fig S1A (B)
906 Proportions (top) and numbers (bottom) of mLN GC Tfh cells in p25 offspring born to and reared
907 by the indicated dams. (C) Proportions (left) and numbers (right) of mLN GC Tfh cells in p25
908 offspring born to $\mu\text{MT}^{+/-}$ dams and fostered to $\mu\text{MT}^{-/-}$ dams at the indicated postnatal timepoints.
909 (D) Similar to (C) comparing $\mu\text{MT}^{-/-}$ born offspring fostered to $\mu\text{MT}^{+/-}$ dams. (E, F) IgA, IgM, and
910 IgG titers (E) and IgG subclass distribution (F) in breastmilk from wild type (WT) B6 dams sampled
911 at the indicated time periods post-parturition. All dams were 12-16 weeks of age. (G) Serum IgG2b
912 levels in $\mu\text{MT}^{-/-}$ pups of the indicated age 2 hours post-gavage with 10mg/kg monoclonal mouse
913 IgG2b antibodies. Lower and upper dotted lines indicate detected IgG2b levels in mice gavaged
914 with PBS or injected intravenously (i.v.) with IgG2b, respectively. (H) Serum FITC-dextran (FITC-
915 dex) titers in WT pups of the indicated age 2 hours post-gavage with 10mg/kg FITC-dex (150kDa).
916 Lower and upper dotted lines indicate detected FITC-dex levels in mice gavaged with PBS or
917 injected i.v. with FITC-dex, respectively. (I) Serum ovalbumin (OVA)-specific IgG1 levels in WT
918 pups of the indicated age 2 hours post-gavage with 10mg/kg monoclonal mouse anti-OVA IgG1
919 antibodies. Lower and upper dotted lines indicate detected OVA-specific IgG1 levels in mice
920 gavaged with PBS or injected i.v. with anti-OVA IgG1, respectively.
921 Error bars indicate the mean \pm standard deviation (SD); symbols represent individual mice. Data
922 are representative of three to four independent experiments with ≥ 5 mice per group. Statistical
923 significance was determined using one-way ANOVA and Tukey post-hoc tests, except (B and G
924 to I), wherein unpaired two-tailed Student's *t* test's were used.

925
926 **Figure 2. Oral IgG is sufficient to restrain Tfh immune dysregulation in offspring lacking**
927 **maternal antibodies.** (A) Milk IgG was fractionated from other proteins using Protein A columns;
928 fractions were concentrated, then fed to offspring of $\mu\text{MT}^{-/-}$ dams and B6 sires during the first
929 week of life. Control pups were fed BSA. (B) Immunoglobulin distribution in milk (input) and
930 following Protein A fractionation into purified milk (m)IgG and eluate (m Δ IgG) components. Milk
931 was isolated from B6 dams at 12-16 weeks of age. (C) Proportions of mLN GC Tfh cells in p25
932 offspring fed 0.5 μg mIgG, 1 μg mIgA (+ other proteins), or 1 μg BSA daily from p0-p7. (D)
933 Immunoglobulin distribution in serum (input) and following Protein A fractionation into purified
934 serum (s)IgG, and eluate (s Δ IgG). Serum was isolated from wild-type mice at 10-16 weeks of age.
935 (E) Proportions of mLN GC Tfh cells in p25 offspring of $\mu\text{MT}^{-/-}$ dams and B6 sires fed 10 μg serum-
936 purified IgG (slgG), IgG-depleted serum (s Δ IgG), PBS, or BSA daily during p0-p7 as indicated.
937 (F), Similar to (E), comparing proportions of mLN GC Tfh cells in littermate, co-housed pups given
938 10 μg slgG or s Δ IgG between p0-p7. Littermate animals are indicated by symbols, and lines
939 connect the mean of co-housed littermates. (G) Similar to (E), comparing p25 mLN GC Tfh
940 frequencies in offspring of $\mu\text{MT}^{+/-}$ dams or of $\mu\text{MT}^{-/-}$ dams fed the indicated concentrations of slgG
941 or BSA between p0-p7.
942 For (B), milk was pooled from approximately two dozen dams, each with ≥ 4 pups aged between
943 4-10 days. Pooled milk was separated by Protein A chromatography, and the antibody
944 composition was determined via ELISA. The indicated fractions from pooled milk were used for
945 all independent experiments. Data are representative of three to four independent experiments
946 with ≥ 3 mice per group, except for C and E, wherein data are combined from two to four replicate

947 experiments and representative of four or more independent experiments. Lines on bar graphs
948 indicate the mean of each replicate, and symbols represent individual mice. For (F), error bars
949 indicate the mean of each litter, and diagonal lines connect the means of co-housed littermates.
950 For (G), error bars indicate the mean \pm SD; symbols represent individual mice. Statistical
951 significance was determined using two-way ANOVA with Sidak post-hoc tests for (C) and (E),
952 one-way ANOVA and Tukey post-hoc tests for (G), and an unpaired two-tailed Student's *t* test for
953 (F).

954
955 **Figure 3. Impact and assembly of the microbiota in maternal antibody-deficient offspring.**
956 (A). Proportions of mLN GC Tfh cells in germ-free p25 offspring born to and reared by the
957 indicated B6.Jh^{-/-} or B6 dams bred with the indicated B6.Jh^{-/-} or B6 sires. (B) Proportions of mLN
958 GC Tfh cells in p25 offspring born to the indicated dams and weaned on the indicated postnatal
959 days. (C) Number of significant differentially abundant taxa (sequence variants) between maternal
960 antibody-sufficient and -deficient offspring isolated from the indicated intestinal sites at the
961 indicated postnatal timepoints. (D) Volcano plots of ileal microbiota taxa (sequence variants) at
962 the indicated postnatal timepoints of mice described in (C). The taxonomic families of significantly
963 altered taxa are indicated by symbols/colors. (E) Non-metric multidimensional scaling plot
964 displaying the Bray-Curtis distances between ileal bacteria from p20 littermate offspring of μ MT^{-/-}
965 dams and B6 sires fed 10 μ g/day slgG or BSA in the first week of life. PERMANOVA analysis:
966 Litter *p*=0.001, *R*²=0.482, *F*=6.98 and IgG feeding group *p*=0.929, *R*²=0.013, *F*=0.218. (F)
967 Heatmap of genus-level ileal taxa (rows) isolated from individual p20 offspring (columns)
968 described in (E) and ordered by complete linkage clustering. Feed and litter status of each mouse
969 is indicated at the top of the heatmap by colors and symbols, respectively. (G) Volcano plot of
970 p20 ileal microbiota species (sequence variants) in mice described in (E). The taxonomic family
971 of the single significantly altered taxa is indicated.
972 For (A to B), error bars indicate the mean \pm SD; symbols represent individual mice. Data are
973 representative of three independent experiments with \geq 3 mice per group. Statistical significance
974 was determined using an unpaired two-tailed Student's *t* test (A) or one-way ANOVA and Tukey
975 post-hoc tests (B). For (C to D), data are combined from two independent experimental cohorts
976 with samples harvested greater than one year apart, totaling $n \geq 10$ /group. For (E to G) data are
977 generated from 3 separate litters with *n*=9 per group. Symbols in (E, G) and columns in (F)
978 represent individual mice.

979
980 **Figure 4. Efficient binding to mucosal antigens is required for early life IgG to restrain**
981 **mucosal Tfh responses.** (A) Serum IgG titers of p7 offspring of the indicated dams that were
982 cross-fostered or fed proteins as indicated. (B to D) Proportion of SYBR+ bacteria bound by IgG
983 as assessed by microbiota flow cytometry (mFLOW). Microbiota was pooled from the small
984 intestine and colon of p6 μ MT^{-/-} neonates and incubated with (B, D) sera or (C, D) milk. (B, C)
985 Graphs depict the mean proportion of IgG bound microbiota from 12 independent serum (B) or
986 breastmilk (C) samples. (D) Graphs depict IgG-bound microbiota following incubation with
987 matched sera and milk from two replicate dams. IgG+ SYBR+ bacteria were gated according to
988 the schematic in Fig S8B. (E) Proportion of SYBR+ bacteria bound by IgG subclasses following
989 incubation of milk or sera isolated from adult (10+ weeks) mice with small intestinal or colonic
990 microbiota isolated from p6 μ MT^{-/-} neonates. (F) Similar to (B) but comparing IgG-bound SYBR+
991 bacteria following incubation with sera of adult (10+ weeks) SPF or germ-free (GF) animals. (G)
992 Proportions of mLN GC Tfh cells in p25 offspring of μ MT^{-/-} dams and B6 sires fed 1 μ g slgG purified
993 from SPF or GF mice, or BSA, as indicated. (H) Serum was collected from TCR β ^{-/-} mice 4 weeks
994 after i.v. injection of BL21 or PBS, and IgG was purified via Protein A fractionation. Timed
995 breedings were performed using co-housed littermate μ MT^{-/-} dams and B6 sires, and resulting
996 offspring were fed slgG, BSA, or BL21 pre-incubated with serum from BL21-immunized (Imm.) or

997 PBS-immunized (Naïve) mice daily in the first week of life. **(I)** Proportions of mLN GC Tfh cells in
998 p25 offspring of μ MT^{-/-} dams and B6 sires fed the indicated proteins +/- bacteria.
999 For **(B to F)** Graphs depict the relative median \pm SD. For **(A, G, and I)** error bars indicate the mean
1000 \pm SD; symbols represent individual mice. Data are representative of two to four independent
1001 experiments with ≥ 2 mice per group. For **G** and **I**, data are combined from two replicate
1002 experiments, representative of three independent experiments, and indicated by symbols. Bars
1003 indicate the mean of each replicate experiment, and statistical significance was determined using
1004 two-way ANOVA and Holm-Sidak post-hoc tests.

1005
1006 **Figure 5. Oral IgG engages Fc-dependent effector functions in the neonate to regulate**
1007 **intestinal homeostasis.** **(A)** Median fluorescence intensity (MFI) expression of Fc γ RII/Fc γ RIII
1008 (CD16/32) by small intestinal cell subsets isolated from WT p7 neonates. Cell subsets comprised
1009 epithelial cells (EpCAM⁺CD45⁻) and myeloid CD45⁺B220⁻CD90.2⁻NK1.1⁻SiglecF⁻ populations,
1010 including cDC1 (MHCII^{hi}CD11C^{hi}XCR1⁺), cDC2 (MHCII^{hi}CD11C^{hi}SIRP α ⁺), neutrophils (Gr-1⁺),
1011 and CX₃CR1⁺ MNPs (MHCII⁺CD11c⁺CX₃CR1⁺Ly6C^{var}). nd = cell population not detected in the
1012 indicated tissue. Cells were gated according to the schematic provided in Fig. S10A **(B)** Timed
1013 breedings were performed with μ MT^{-/-} dams and B6 sires and IgG sensor-deficient dams and
1014 sires including FcR γ ^{-/-}, C1qa^{-/-}, and C1qa^{-/-}FcR γ ^{-/-} pairs. At birth, a portion of offspring of μ MT^{-/-}
1015 dams and B6 sires were replaced with age-matched IgG sensor-deficient offspring. All offspring
1016 were fed 10 μ g purified slgG or BSA daily in the first week of life. **(C)** Proportions of mLN GC Tfh
1017 cells in p25 FcR γ ^{-/-} or μ MT^{+/-} offspring fed the indicated proteins in the first week of life. **(D)** Similar
1018 to **(B)** comparing C1qa^{-/-} and μ MT^{+/-} offspring. **(E)** Similar to **(B)** comparing C1qa^{-/-}FcR γ ^{-/-} and
1019 μ MT^{+/-} offspring. **(F)** Offspring of μ MT^{-/-} dams and B6 sires were fed 10 μ g purified slgG or BSA
1020 daily in the first week of life. At p16-18, offspring were given 1-10x10⁵ CD45.1⁺CD4⁺ OVA-specific
1021 OTII transgenic T cells and administered OVA in drinking water until analysis at p25/p26. Controls
1022 were given regular drinking water. **(G to J)** Cells were gated according to the schematics provided
1023 in Fig S4D and Fig S11E. **(G)** Proportions of mLN OVA-specific CD45.1⁺V α 2⁺V β 5.1⁺CD4⁺Foxp3⁺
1024 pTreg cells in p25 offspring given the indicated treatments as described in **(F)**. **(H)** Similar to **(G)**
1025 but comparing proportions of mLN OVA-specific CD45.1⁺V α 2⁺V β 5.1⁺Foxp3⁻CD44^{hi}FR4⁺CD73⁺
1026 Th^{lin}- cells. **(I)** Similar to **(G)** but comparing proportions of mLN OVA-specific CD45.1⁺V α 2⁺V β 5.1⁺
1027 GC Tfh cells. **(J)** Pie chart depicting fraction of GC Tfh, Treg, Th^{lin}- and 'other' subsets of total
1028 activated CD44^{hi}CD45.1⁺V α 2⁺V β 5.1⁺ OVA-specific T cells of offspring described in **(F)**. Numbers
1029 in legends indicate the mean percentage of events (\pm SD) of all samples within the experiment.
1030 **(K)** Ileal OVA-specific IgE titers of p40 offspring given the indicated treatments as described in
1031 **(F)**.

1032 For **(A, C to E, G to I, and K)** Error bars indicate the mean \pm SD; symbols represent individual
1033 mice. Data are representative of two to four independent experiments with ≥ 2 mice per group. For
1034 **A**, data are representative of two independent experiments, with ≥ 2 samples per group, and 3-4
1035 mice pooled per sample. For **D**, data are combined from three replicate experiments indicated by
1036 symbols. For **(C, E)**, statistical significance was determined using one-way ANOVA and Tukey
1037 post-hoc tests. For **(D)**, statistical significance was determined using two-way ANOVA and Holm-
1038 Sidak post-hoc tests. For **(G to I, and K)**, statistical significance was determined using an
1039 unpaired, two-tailed Student's *t* test.

1040
1041